Archive for the ‘Nutrition and Cancer’ Category

Federal Judge Tosses Medical Marijuana Case

Comments Off
Posted 07 Jan 2012 — by James Street
Category Cannabis, Finance and Politics of cancer research and treatment, Legal, Marijuana

By Emily P. Walker, Washington Correspondent, MedPage Today
Published: January 06, 2012

A federal judge has thrown out Arizona governor Jan Brewer’s complaint against the state’s medical marijuana law.

The law, passed in 2010, created a system of marijuana dispensaries that are regulated by the state’s health department. Patients are banned from growing their own marijuana if they live within a 25-mile radius of a dispensary.

Brewer and the state’s attorney general filed the lawsuit just days before the state was scheduled to accept applications from potential dispensary operators. The suit asked for a judgment on whether state officials who administer Arizona’s medical marijuana programs could be at risk for federal prosecution, since marijuana is illegal under federal law.

U.S. District Judge Susan Bolton of Arizona on Wednesday dismissed the complaint, ruling that the Arizona officials failed to show that an imminent threat of prosecution exists for state employees, or that state employees in any of the 16 states with medical marijuana laws have faced prosecution for violating federal laws that make marijuana use and dispensing illegal.

Recently, federal authorities in California began cracking down on the state’s medical marijuana industry, but they are targeting those who are dispensing the drug illegally, and have said those who need marijuana for medical purposes — such as to help ease the effects of cancer or AIDS — will still be able to get it.

Even if the threat of prosecution for state employees in Arizona were imminent, Brewer and the other plaintiffs in the case — the director of the Arizona Department of Health Services and the director of the Arizona Department of Public Safety — didn’t show they would suffer direct harm or immediate hardship if the case wasn’t immediately decided, Bolton wrote, so the case is “not appropriate for judicial review.”

Matthew Benson, director of communications for Brewer’s office, called the ruling a disappointment.

“What this federal court has essentially said is, it won’t hear the state’s lawsuit until a state employee is prosecuted or notified that they imminently face federal prosecution for their part in administering Proposition 203,” he said in an email to MedPage Today.

The American Civil Liberties Union (ACLU) praised the decision.

“It is unconscionable for Governor Brewer to continue to force very sick people to needlessly suffer by stripping them of the legal avenue through which to obtain their vital medicine,” Ezekiel Edwards, director of the ACLU Criminal Law Reform Project, said in a press release. “[The] ruling underscores the need for state officials to stop playing politics and implement the law as approved by a majority of Arizona voters so that thousands of patients can access the medicine their doctors believe is most effective for them.”

In addition to Arizona, 15 other states have medical marijuana laws — Alaska, California, Colorado, Delaware, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, and Washington. Medical marijuana also is legal in District of Columbia.

More Cannabis Science Brand Extracts Successful Cancer Treatments Confirmed As Self Medicating Squamous Cell Carcinoma Patient Reports Continued Shrinking of Cancer Tumor

Comments Off
Posted 03 Jan 2012 — by James Street
Category Cannabis, Marijuana

COLORADO SPRINGS, Colo., Jan 03, 2012 (BUSINESS WIRE) — Cannabis Science, Inc. CBIS 0.00% a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products. The Company is very pleased to report the continuing successful progress by patient who has been topically self-administering Cannabis Science extracts for Squamous Cell Carcinoma Cancer. Cannabis Science is in a unique position to evaluate the effectiveness of different formulations by working closely with physicians and patients in medical marijuana states where patients can determine the effectiveness of various cannabis-based formulations.

For example, as previously announced, this patient has photo-documented dramatic shrinkage and subsequent disappearance in the cancer tumor. We will release documentation to the public once treatment is completed and has been properly confirmed by clinical biopsy.

Cannabis Science is focused on establishing clinically confirmed data that will lead to standardized products under the Cannabis Science label, thus confirming the numerous anecdotal reports confirming the anti-cancer properties of whole cannabis and cannabinoid extracts.

Cannabis Science is committed to making cannabis-based medicines available to the public as rapidly as possible. The Company is taking multiple approaches to accomplishing this aim in the United States. The science of cannabinoids has exploded over the past decade, laying the scientific foundation for the many medicinal uses of this unique plant. Cannabinoids are a class of biologically active compounds produced by all vertebrates (endocannabinoids) the Cannabis plant (phytocannabinoids), and more recently patentable synthetic compounds produced by chemists. Today’s modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.

Cannabis Science, in conjunction with several Colorado-licensed dispensaries and physicians, consults with a number of cancer patients who were seeking to inform themselves of the current peer-reviewed scientific literature, regarding modern and historical use of cannabis preparations for treating cancers so that they can make informed decisions regarding their self-directed, self administered cancer treatment.

The first two Cannabis Science Brand Formulations, Cannabis Science CT-1 and Cannabis Science MT-1 are now available at both Cannabis Therapeutics and Marisol Therapeutics exclusively for Colorado State licensed medical marijuana patients.

Cannabis Science MT-1: Produced by Marisol Therapeutics: A family-owned shop, Marisol Therapeutics was founded to assist medical marijuana patients in obtaining medical marijuana in Colorado. They believe patients have the right to safe, confidential, quality medical marijuana and products. They recommend medical marijuana from their own experience with unrelenting and previously untreatable pain. “We understand, we care, we want you to heal.” Marisal Therapeutics has produced a custom blend of but is derived from their proprietary strains that were developed over 30 years by a Native American Vietnam veteran in order to address his medical needs. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds. The product is produced in soil under organic roof conditions.

ADDRESS: 922 Kimble Drive, Pueblo West, CO 81007

PHONE: 719-547-4000

EMAIL: info@marisolmed.com or http://marisolmed.com/ for more information.

Cannabis Science CT-1: Produced by Cannabis Therapeutics was Colorado’s first dispensary. Working with local law enforcement, state officials, legal experts, medical physicians, and researchers, Cannabis Therapeutics sets a standard of both safety and consistent quality to its members as well as the community at large. Cannabis Therapeutics is a professional medical business that employs all its policies and regulations to ensure the most stringent adherence to the law. Second in importance to legality is implementation of standardizing techniques to ensure both repeatability in dosing and quality of medicine. Cannabis Therapeutics began as an organization built by individuals that did not receive satisfactory relief from conventional therapies. Cannabis Therapeutics has produced a high quality cannabis extract from a custom blend of buds hydroponically grown medical marijuana strains. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds.

ADDRESS: 907 E Fillmore St., Colorado Springs, CO 80907

http://www.cannabistherapeutics.net/ for more information.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

SOURCE: Cannabis Science, Inc.

Saffron Spice Fights Liver Cancer

Comments Off
Posted 26 Dec 2011 — by James Street
Category Liver, Saffron

December 25, 2011

Great news just in time for Christmas: Arab scientists from the United Arab Emirates have located anti-cancer compounds in the much loved and expensive spice saffron. Known for centuries as a home remedy, the research project led by Professor Amr Amin from the United Arab Emirates University, Al Ain, found that saffron is able to suppress a large variety of cancer compounds. This news reported in the journal Hepetology, puts saffron in the ranks of cancer fighter along with another much-loved Asian spice, tumeric.

In the experiment on saffron, the researchers found that saffron is able to boost compounds in the body to help the body fight off cancer.”We are excited to learn more about the molecular aspects of how saffron works, we are strong believers that an immediate clinical trial [testing saffron in liver cancer patients] will benefit a wide spectrum of cancer patients not only in the UAE but worldwide as well,” Amin told the Gulf News.

The experiment used rats who were given liver cancer. A control group did not receive saffron, while an experimental group did. Seventy-five percent of the rats in the control group developed cancer, versus 16% in the saffron group which did not. Those rats that got the highest doses of saffron did not develop cancer nodules at all.

The researcher believes that the molecules in saffron can also fight off a range of cancers, and they are planning on revealing more research in this direction soon.

In the journal the researchers concluded: “This study provides evidence that saffron exerts a significant chemopreventive effect against liver cancer through inhibition of cell proliferation and induction of apoptosis. This report also shows some evidence that saffron protects rat liver from cancer via modulating oxidative damage and suppressing inflammatory response.”

Saffron, one of the most expensive spices on the market, comes from the stamen of the saffron flower. It is used in Arab and Central Asian cuisine, but its cancer-fighting properties have only been tested recently. Amin believes that it can also fightdepression, inflammation and memory loss.

Another Middle East wonder spice, saffron joins tumeric, and black cumin seeds (and oil) for potentially remarkable cancer-fighting properties. Now we just need a recipe that includes all three.

::Gulf News

Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α

Comments Off
Posted 14 Dec 2011 — by James Street
Category Green Tea (Epigallocatechin-3-gallate), HIF-1α, Hypoxia, Lung Cancer, MicroRNA, miR-210
  1. Hong Wang*,
  2. Shengjie Bian and
  3. Chung S. Yang

+ Author Affiliations


  1. Susan L. Cullman Laboratory for Cancer Research, Department of Chemical Biology and Center for Cancer Prevention Research, Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, NJ 08854, USA
  1. *To whom correspondence should be addressed. Tel: +1 732 445 3400; Fax: +1 732 445 0687;Email: howang@rci.rutgers.edu
  2. Correspondence may also be addressed to Chung S. Yang. Email: csyang@rci.rutgers.edu
  • Received May 3, 2011.
  • Revision received September 21, 2011.
  • Accepted September 24, 2011.

Abstract

(−)-Epigallocatechin-3-gallate (EGCG) has been reported to affect many cellular regulatory pathways. This study aims to determine whether EGCG could target microRNA (miRNA), one of the mechanisms for cells to achieve subtle change in multiple targets. We found that, in both human and mouse lung cancer cells in culture, EGCG specifically upregulated the expression of miR-210, a major miRNA regulated by HIF-1α. Furthermore, we found that overexpression of miR-210 led to reduced cell proliferation rate and anchorage-independent growth as well as reduced sensitivity to EGCG. On the mechanisms of miR-210 regulation by EGCG, we demonstrated that the regulation was mediated through the hypoxia-response element in miR-210 promoter. Consistently, the upregulation of miR-210 was found to be correlated with the stabilized HIF-1α in lung cancer cell lines after EGCG treatment. This EGCG-induced stabilization of HIF-1α was further shown by the stabilization of HA-tagged HIF-1α but not the P402A/P564A-mutated HIF-1α by EGCG, suggesting that EGCG targets the oxygen-dependent degradation (ODD) domain. Direct evidence was obtained by affinity binding assay showing that EGCG specifically binds HIF-1α with a Kd = 3.47 μM. This result suggests that EGCG binding interferes with the hydroxylation of key Pro residues in the ODD domain, preventing HIF-1α from the Pro hydroxylation-dependent ubiquitination and subsequent proteosome-mediated degradation. In summary, our results demonstrated, for the first time, the elevation of miR-210 by EGCG in lung cancer cell lines and this is mediated by the stabilization of HIF-1α. This event contributes to the anticancer activity of EGCG.

  • Abbreviations
    EGCG
    (−)-epigallocatechin-3-gallate
    HIF
    hypoxia-induced factor
    HRE
    hypoxia-response element
    mRNA
    messenger RNA
    miRNA
    microRNA
    MTT
    3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide
    ODD
    oxygen-dependent degradation
    PCR
    polymerase chain reaction
    PHD
    prolyl-hydroxylase
    SOD
    superoxide dismutase

Boosting the Effectiveness of Cancer Therapies Anti cancer therapies improved when tumors injected with dopamine

Comments Off
Posted 06 Dec 2011 — by James Street
Category Chemotherapy, Dopamine, Hypoxia
Published:  Dec 5, 2011 02:12 pm

(dailyRx)

Cancer tumors create their own network of blood vessels to stay alive. Scientists have found a way to use this network to enhance the effects of cancer treatments.

Injecting animal tumors with the neurotransmitter dopamine has been shown to improve the delivery and effectiveness of anticancer drugs. The dopamine also increases oxygen levels in the tumor, which usually improves the effectiveness of both chemotherapy drugs and radiation therapy.

These are the findings of a study conducted at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Lead investigator Dr. Sujit Basu says the use of dopamine may hold promise in treating not only cancer, but other conditions in which normalizing blood vessel function could improve treatment response.

Tumors develop blood vessels, but they don’t do a very good job of supplying blood to the tumor. This in turn limits the ability of chemotherapy drugs to be delivered to the tumor and deprives the mass of oxygen. Tumor cells that don’t have adequate oxygen become resistant to both drugs and radiation.

Dr. Basu and his colleagues found that the tumor tissue used in the study lacked dopamine. When the tissue was treated with the neurotransmitter, the tumor blood vessels regained normal appearance and function.

Mice model human colon cancer tumors injected with dopamine accumulated twice the amount of chemotherapy drug administered and were one-third the size of tumors treated with the chemotherapy agent only.

“Overall, our findings suggest that the normalization of tumor blood vessels using the neurotransmitter dopamine might be an important approach for improving therapeutic efficacy in the treatment of cancer patients,” said Basu, associate professor of pathology and a researcher in the OSUCCC – James Experimental Therapeutics Program.

Findings from this study are published online in the Proceedings of the National Academy of Sciences.

Cannabinoids for Cancer Treatment: Progress and Promise

Comments Off
Posted 27 Nov 2011 — by James Street
Category Marijuana

http://cancerres.aacrjournals.org/content/68/2/339.abstract

Cannabinoids for Cancer Treatment: Progress and Promise

Abstract

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of cannabinoid receptors expressed by tumor cells may offer a novel strategy to treat cancer. Here, we review recent work that raises interest in the development and exploration of potent, nontoxic, and nonhabit forming cannabinoids for cancer therapy. [Cancer Res 2008;68(2):339–42]

Articles citing this article

  • Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis Cancer Prev Res January 1, 2011 4:65-75
  • A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma Molecular Cancer Therapeutics January 1, 2011 10:90-103
  • The Levels of the Endocannabinoid Receptor CB2 and Its Ligand 2-Arachidonoylglycerol Are Elevated in Endometrial Carcinoma Endocrinology March 1, 2010 151:921-928
  • Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer Molecular Cancer Therapeutics November 1, 2009 8:3117-3129
  • Potentiation of Cannabinoid-Induced Cytotoxicity in Mantle Cell Lymphoma through Modulation of Ceramide Metabolism Mol Cancer Res July 1, 2009 7:1086-1098
  • Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor {alpha}-Mediated Ceramide De novo Synthesis in Colon Cancer Cells Clin. Cancer Res. December 1, 2008 14:7691-7700

The Medical Miracle You’ll Get Arrested for Using

Comments Off
Posted 27 Nov 2011 — by James Street
Category Marijuana
Posted By Dr. Mercola | November 26 2011 | 97,982 views

Story at-a-glance

  • Fifteen states plus the District of Columbia have laws permitting medical marijuana, but the Drug Enforcement Agency (DEA) has raided medical marijuana suppliers and even arrested patients, because on a federal level, possessing or distributing marijuana is still considered a criminal offense
  • In 2009, the U.S. Justice Department told federal prosecutors to lay off Americans producing and using medical marijuana in accordance with state laws, but this year in a blatant about-face, the Obama administration declared that only seriously ill patients and caregivers would be spared from arrest
  • Recently, a series of attacks against the medical marijuana industry have occurred, including threats against banks and landlords that do business with those in the industry. Also, the IRS has denied medical cannabis facilities in California the right to file standard expense deductions. These strong-arm tactics put the medical marijuana industry in jeopardy, and may force those who depend on it for medical purposes to resort to the black market
  • Research shows medical marijuana holds promise in the treatment of over 100 health conditions, including cancer, autoimmune diseases, pain, glaucoma, asthma, psychiatric conditions and high blood pressure.
  • Fifty percent of Americans now support the legalization of marijuana

 

By Dr. Mercola

Marijuana was a popular botanical medicine in the 19th and 20th centuries, common in U.S. pharmacies of the time.

Yet, in 1970, the herb was declared a Schedule 1 controlled substance and labeled as a drug with a “high potential for abuse” and “no accepted medical use.”

Three years later the Drug Enforcement Agency (DEA) was formed to enforce the newly created drug schedules, and the fight against marijuana use began.

The Huffington Post has a concise history of marijuana prohibition, and the struggle for legalization, that is well worth reading — but the most successful movement to date, and the one that is set to produce the first legal marijuana market in decades, is the medical marijuana movement.

Unfortunately, the feds have recently announced a blatant reversal on their previous pro-medical marijuana stance — a move that is threatening to stop the industry cold.

Why are the Feds So Concerned About Medical Marijuana?

Fifteen states plus the District of Columbia have laws allowing medical marijuana.

In other words, in those states it is considered legal to consume, possess or distribute marijuana for medical use.

Up until 2009, the U.S. Justice Department essentially told federal prosecutors to lay off Americans producing and using medical marijuana in accordance with state laws.

But despite marijuana’s legal status at the state level, historically it was common for the DEA to raid medical marijuana suppliers and even arrest patients.

This is because federal law overrides state law, defining the possession or distribution of marijuana as a criminal offense.

According to The State of the Medical Marijuana Markets 2011, the national market for medical marijuana is now worth $1.7 billion — and could grow to close to $9 billion in the next five years — if not for a stunning reversal by the Obama administration. In October 2011, the Obama administration released a letter to clarify their earlier position, which, as Seattle Weekly reports, indicates, “The only people safe from arrest were the “seriously ill” patients and their caregivers… Everyone else? Be forewarned.”

The Obama administration has long been supportive of the medical marijuana movement, even stating during the presidential campaign that, “The basic concept of using medical marijuana… [is] entirely appropriate.” However the Feds now appear to be launching a full-fledged attack against this legitimate industry, not only by threatening prosecution and arrest, but also by intimidating and coercing banks, land and store owners, as well as other business entities, that help keep the medical marijuana industry alive.

Feds Attempt to Force Medical Marijuana Industry Out of Business

In recent months there have been several blows to the various industries who support the medical marijuana market. Paul Armentano, deputy director of NORML, the National Organization for the Reform of Marijuana Laws, reported in U.S. News & World Report Opinion, these disturbing changes:

  • “The Department of Justice sent letters this past spring to state lawmakers that were debating legislation to allow for the licensed distribution of medical cannabis, threatening prosecution of those involved with said efforts if the measures went forward;
  • The IRS has assessed crippling penalties on taxpaying medical cannabis facilities in California by denying these operations the right to file standard expense deductions;
  • The Department of Treasury has strong-armed local banks and other financial institutions into closing their accounts with medicinal cannabis operators;
  • The Drug Enforcement Administration has rejected a nine-year-old administrative petition that called for hearings regarding the federal rescheduling of cannabis for medical use, ignoring extensive scientific evidence of its medical efficacy;
  • The National Institute on Drug Abuse rejected an FDA-approved protocol to allow for clinical research assessing the use of cannabis to treat post-traumatic stress disorder, stating, “We generally do not fund research focused on the potential beneficial medical effects of marijuana.”
  • Most recently, Deputy Attorney General James Cole, along with the four U.S. attorneys from California, announced plans for a coordinated effort against operations in California that provide above-ground access to cannabis for those patients qualified to use the substance in accordance with state law.”

The war on marijuana is indeed a strange one, considering the legality of cigarettes and alcohol — products that have vastly greater potential to harm public health, without any of the medicinal benefits. Not to mention that the FDA approves drugs, prescribed by doctors every day, that kill over 100,000 Americans a year.

Moreover, by shutting down reputable marijuana dispensaries, it will only force those who legitimately depend upon it to alleviate their suffering to enter the (sometimes dangerous) black market.

As Seattle Weekly wrote:

“Landlords, worried the feds will steal their property, will tell dispensaries to move out. Banks won’t handle money for pot-themed businesses. Dispensaries will be taxed so heavily they won’t be able to cover the payroll or pay the electric bill.

… An estimated one million people in California have obtained a doctor’s recommendation to grow and use marijuana legally. Patient estimates in Washington are hazier, but the number is thought to be around 100,000.

If the feds shut down every dispensary in the country, all these people will still be able to legally possess marijuana—no matter where they bought it—under their state laws. The only difference is they’ll be forced to go back to buying their weed from Mexican drug cartels, rather than from Americans who provide jobs and pay taxes.”

What are the Medical Uses for Marijuana?

In order to really comprehend the movement behind medical marijuana, you must first understand that this herb truly does show outstanding promise as a medicinal plant. The studies conducted so far show significant potential for the use of cannabis in the prevention and treatment of a wide range of health conditions, including cancer.

For instance, in 2009 a study in the journal Cancer Prevention Research found that marijuana smokers have a lower risk of head and neck cancers than non-marijuana smokers.

Harvard researchers also found that THC in marijuana cuts tumor growth in lung cancer while significantly reducing its ability to spread. There is also a wealth of research linking marijuana with pain relief and improved sleep. In one recent study, just three puffs of marijuana a day for five days helped those with chronic nerve pain to relieve pain and sleep better.

Americans for Safe Access also has links to research studies suggesting that cannabis may help in the treatment or prevention of Alzheimer’s disease and cancer, while the International Association for Cannabis as Medicine highlights the following medical uses:

Nausea Vomiting Anorexia Cachexia (Wasting Syndrome)
Spasticity Movement Disorders Pain Glaucoma
Epilepsy Asthma Dependency and Withdrawal Psychiatric Symptoms
Autoimmune Diseases Inflammation High Blood Pressure Chronic Fatigue Syndrome

 

Lastly, the research site GreenMedInfo.com lists over 126 potential therapeutic applications for marijuana in disease prevention and treatment, further illustrating just how voluminous the scientific evidence really is in support of the medical marijuana movement.

Your Body is Hard-Wired to Respond to Cannabinoids in the Marijuana Plant

There are more than 60 chemical compounds known as cannabinoids in the marijuana plant. Cannabinoids interact with your body by way of naturally occurring cannabinoid receptors embedded in cell membranes throughout your body. There are cannabinoid receptors in your brain, lungs, liver, kidneys, immune system and more; both the therapeutic and psychoactive properties of marijuana occur when a cannabinoid (such as the THC produced by the cannabis plant) activates a cannabinoid receptor.

Your body also has naturally occurring endocannabinoids that stimulate your cannabinoid receptors and produce a variety of important physiologic processes, far beyond that of the traditional “highs” associated with THC.

What is amazing is that your body is actually hard-wired to respond to cannabinoids through this unique cannabinoid receptor system; research is still ongoing on just how extensive their impact is on our health, but to date it’s known that cannabinoid receptors play an important role in many body processes, including metabolic regulation, cravings, pain, anxiety, bone growth, and immune function.

A report by Dr. Manuel Guzman in the journal of Nature Reviews suggests that these active components of cannabis and their derivatives are potential anti-cancer agents:

” … these compounds [cannabinoids] have been shown to inhibit the growth of tumour cells in culture and animal models by modulating key cell-signaling pathways. Cannabinoids are usually well tolerated, and do not produce the generalized toxic effects of conventional chemotherapies.”

A report by the American College of Physicians (ACP) further notes that:

Marijuana has been smoked for its medicinal properties for centuries. It was in the U.S. Pharmacopoeia until 1942 when it was removed because federal legislation made the drug illegal … Still, the overwhelming number of anecdotal reports on the therapeutic properties of marijuana sparks interest from scientists, health care providers, and patients.

Over the past 20 years, researchers have discovered cannabinoid receptors: CB1, which mediates the central nervous system (CNS), and CB2, which occurs outside the CNS and is believed to have anti-inflammatory and immunosuppressive activity.

These scientific developments have revealed much information supporting expansion of research into the potential therapeutic properties of marijuana and its cannabinoids.”

Why Isn’t Marijuana Being Studied?

This is the burning question, as even a quick review of the data suggests that cannabis deserves more than a passing glance as a potential treatment for various diseases. But in the United States – primarily for political reasons — these studies are not being performed.

According to a report by Americans for Safe Access:

“In the past three decades, there has been an explosion of international studies designed to investigate the therapeutic value of cannabis (marijuana).

However, drastic restrictions on research in the U.S. have meant that few clinical trials are being conducted domestically and none are being conducted as part of a sponsor-funded drug development plan aimed at obtaining Food & Drug Administration (FDA) approval for the prescription use of the botanical plant itself.

Meanwhile, research teams in Great Britain, Spain, Italy, Israel, and elsewhere have confirmed – through case studies, basic research, pre-clinical, and preliminary clinical investigations – the medical value of cannabis … ”

Of course, in the United States marijuana is so heavily controlled that even if you wanted to conduct a clinical trial, you would have a hard time getting a supply for research purposes. As the Safe Access report states:

” … the federal monopoly on the supply of cannabis has fundamentally limited FDA-approved clinical research to investigate its safety and efficacy in controlling symptoms of serious and chronic illnesses.

In the United States, research is stalled, and in some cases blocked, by a complicated federal approval process, restricted access to research-grade cannabis, and the refusal of the Drug Enforcement Administration (DEA) to license private production of cannabis for use exclusively in federally approved research.”

The DEA appears to be behind many puzzling restrictions concerning the marijuana plant, including the fact that it is even illegal to grow hemp in the United States.

Contrary to popular opinion, hemp and marijuana are not the same. Both are members of the Cannabis sativa plant species, but they are two distinct varieties, with hemp generally being too low in THC (the compound responsible for the plant’s notorious psychoactive effect) to create a “high.” In fact, the THC is intentionally bred out of the plant in order to maximize its fiber, seeds and oil — the constituents for which it is most commonly used.

Ironically, despite these differences, the DEA classifies all Cannabis sativa varieties as “marijuana.” This is why the United States is the only industrialized nation in the world where growing industrial hemp is next to impossible. To do so requires a permit from the DEA — and it is reportedly almost impossible to get one.

Could it be that the DEA has its own agenda for keeping marijuana a controlled substance?

Seattle Weekly speculates:

“Ignorance, false propaganda, and rank political posturing tend to be the foundation of the anti-marijuana argument. (Throw in bureaucratic turf protection as well. The DEA, for example, would need fewer agents if pot was decriminalized nationwide.)”

Many Americans Have an Open Mind About Legalizing Marijuana

A new Gallup poll found that a record high number of Americans — 50 percent — favor legalizing marijuana use, which suggests that public pressure will continue to build for a (pun-intended) grassroots legislative overhaul of U.S marijuana laws…

Of course, there are certainly some downsides to marijuana use that need to be addressed, particularly if you are thinking of smoking it for recreational purposes.

Marijuana use can be addictive, and no doubt resources have been squandered, families have been broken up and jobs lost over its use. In the short-term, marijuana use can cause trouble with your ability to think clearly and may impair memory. Marijuana also leads to motor skill impairment and may adversely affect alertness, coordination and reaction time, which is why it should never be used prior to driving.

There is also some evidence that marijuana use can exacerbate psychotic symptoms in those with schizophrenia or other psychotic disorders, as well as serve as a “gateway” drug that eventually leads to the use of “harder” drugs like cocaine and heroine, although this is still a matter of debate.

Marijuana use among children and teens can also have dire consequences, as drug use of any kind may encourage risky choices and irresponsible behaviors.

Furthermore, while the vast majority of marijuana use is through the act of smoking it, it is worth noting that anytime you heat materials and inhale them you run the risk of introducing toxic elements into your system. Because of this it is always best to use an organic version; any pesticides that are on the material that is burned and inhaled will dramatically increase its toxicity.

It is possible to avoid these risks entirely by either using cannabis in hemp oil form or, as many medical marijuana patients advocate, by using a vaporizer. The device allows for the ingestion of marijuana without any combustion byproducts, eliminating rightful concerns about the cumulative harms associated with smoking it. It is also possible to minimize harm by eating marijuana (along with some fat, as THC is fat-soluble and will not dissolve in water).

It is important to note that in the United States today using marijuana for any reason is still considered an illegal activity that can result in serious legal consequences, including imprisonment.

Sadly, it is not the scientific evidence — but rather politics and an increasingly insatiable privatized industrial-prison complex in need of more drug-convicted “criminals” — which maintains the stranglehold on our freedom to choose wild growing plants as our medicine rather than soley FDA-approved drugs.

I think Willie Nelson said it well in the following quote:

I think people need to be educated to the fact that marijuana is not a drug. Marijuana is an herb and a flower. God put it here. If He put it here and He wants it to grow, what gives the government the right to say that God is wrong?

Modified Citrus Pectin (MCP)–retards cancer growth and metastasis

Comments Off
Posted 21 Nov 2011 — by James Street
Category Diet and Prostate Cancer, Lung Metastases, Metastases, Modified Citrus Pectin (MCP), Prostate Cancer, PSA testing

Modified citrus pectin (MCP), also known as fractionated pectin, is a complex polysaccharide obtained from the peel and pulp of citrus fruits. Through pH and temperature modifications, the pectin is broken down into shorter, nonbranched, galactose-rich, carbohydrate chains. The shorter chains dissolve more readily in water, making them better absorbed than ordinary, long-chain pectin. The short polysaccharide units afford MCP its ability to access and bind tightly to galactose-binding lectins (galectins) on the surface of certain types of cancers. By binding to lectins, MCP is able to powerfully address the threat of metastasis (Strum et al. 1999).

In order for metastasis to occur, cancerous cells must first bind or clump together; galectin is thought responsible for much of cancer’s metastatic potential by providing the binding site (Raz et al. 1987; Guess et al. 2003; Pienta et al. 1995). MCP appears small enough to access and bind tightly with galectins, inhibiting (or blocking) aggregation of tumor cells and adhesion to surrounding tissue (Kidd 1996). Deprived of the capacity to adhere, cancer cells fail to metastasize.

Men with prostate cancer who took 15 grams of MCP a day had a slowdown in the doubling time of their PSA levels. (Lengthening of doubling time represents a decrease in the rate of cancer growth.) Interestingly, rats injected with prostate adenocarcinoma and given MCP (in drinking water) showed a significant reduction in metastasis (compared to control animals), although the primary tumor was unaffected. According to Dr. Kenneth Pienta (leader of the Michigan Cancer Foundation), MCP may be the first oral method of preventing spontaneous prostate cancer metastasis (Pienta et al. 1995; Guess et al. 2003).

As with prostate adenocarcinoma, research shows that metastasis of breast cancer cell lines requires aggregation and adhesion of the cancerous cells to tissue endothelium in order for it to invade neighboring structures (Glinsky et al. 2000). To test the anti-adhesive properties of MCP, researchers evaluated (in an in vitro model) breast carcinoma cell lines MCF-7 and T-47D. The study concluded that MCP countered the adhesion of malignant cells to blood vessel endothelium and subsequently inhibited metastasis (Naik et al. 1995). MCP decreased metastasis of melanoma to the lung by more than 90% in laboratory animals (Platt et al. 1992).

Because MCP is a soluble fiber, no pattern of adverse reaction has been recorded in the scientific literature, apart from a self-limiting loose stool at high doses. MCP dosages are usually expressed in grams, with a typical adult dose ranging from 6-30 grams divided throughout the day. MCP’s apparent safety and proven antimetastatic action, and the lack of other proven therapies against metastasis appear to justify its inclusion in a comprehensive orthomolecular anticancer regimen (Kidd 1996). Pecta-Sol is the brand name of the original modified citrus pectin (MCP. The dosage for Pecta-Sol is about 15 grams a day.

Lactoferrin–is immunoregulatory, inhibits angiogenesis, and binds iron

Comments Off
Posted 21 Nov 2011 — by James Street
Category Antiagiogenesis, antiangiogenesis, lactoferrin

Lactoferrin–is immunoregulatory, inhibits angiogenesis, and binds iron
Perhaps one of the most promising therapeutic uses of lactoferrin, a milk protein with bacteriostatic properties, may be as a nontoxic, anticancer agent. Lactoferrin, a minor fraction of whey, results in a significant reduction in the incidence of esophageal, lung, bladder, and colon cancer in laboratory rats (Ushida et al. 1999; Masuda et al. 2000; Tsuda et al. 2002).

Since evidence indicates milk products protect against colon cancer, researchers speculate that bovine lactoferrin, a natural ingredient in milk, may be the chemoprotective agent (Tsuda et al. 2000b). Rats treated with a carcinogen and supplemented with 2% bovine lactoferrin for 36 weeks had a reduced incidence of colon cancer (27% of that observed in a control group; rats receiving 0.2% bovine lactoferrin reduced incidence to 46%). A remarkable 43% reduction in spontaneous lung metastasis (compared to controls) occurred after implanting colon carcinoma 26 (Co 26 Lu) in lactoferrin-treated laboratory animals (Tsuda et al. 2000a).

In addition to inhibiting angiogenesis (the vascular network that sustains the tumor), lactoferrin maintains the integrity of the immune system (Yoo et al. 1997; Tsuda et al. 2002). Typically, bovine lactoferrin prompts an increase in the number of natural killer cells, as well as the cytotoxicity of white blood cells (Tsuda et al. 2000a). The antibiotic, anti-inflammatory, and immune-modulating properties of lactoferrin appear active against the gastritis-, ulcer-, and cancer-inducing bacterium Helicobacter pylori (Dial et al. 2002).

Lactoferrin, a natural iron-binding protein, scavenges free radicals in fluids and inflamed areas, suppressing free radical mediated damage. It decreases the availability of iron in neoplastic cells, depriving them of an iron supply (Khan et al. 2001; Weinberg 2001).

The suggested dosage is 300-900 mg a day of the superior apolactoferrin (iron-depleted) form of lactoferrin. Lactoferrin is a natural component of cows’ and human mothers’ milk, but is also found in the milk of sheep, goats, and pigs.

Tyrosine Isomers Mediate the Classical Phenomenon of Concomitant Tumor Resistance

Comments Off
Posted 19 Nov 2011 — by James Street
Category Metastases, metastases, Tyrosine
  1. Raúl A. Ruggiero1,
  2. Juan Bruzzo1,
  3. Paula Chiarella1,
  4. Pedro di Gianni1,
  5. Martín A. Isturiz1,
  6. Susana Linskens2,
  7. Norma Speziale2,
  8. Roberto P. Meiss3,
  9. Oscar D. Bustuoabad1, and
  10. Christiane D. Pasqualini1

+ Author Affiliations


  1. Authors’ Affiliations:1División Medicina Experimental, Academia Nacional de Medicina; 2Facultad de Farmacia y Bioquímica, UBA; and 3Instituto de Estudios Oncológicos, Academia Nacional de Medicina, Buenos Aires, Argentina
  1. Corresponding Author:
    Raúl A. Ruggiero, División Medicina Experimental, Academia Nacional de Medicina, Pacheco de Melo 3081 (1425), Buenos Aires, Argentina. Phone: 54-11-4805-3411; Fax: 54-11-4803-9475; E-mail: ruloruggiero@yahoo.com.ar

Abstract

Concomitant tumor resistance (CR) is a phenomenon originally described in 1906 in which a tumor-bearing host is resistant to the growth of secondary tumor implants and metastasis. Although recent studies have indicated that T-cell–dependent processes mediate CR in hosts bearing immunogenic small tumors, manifestations of CR induced by immunogenic and nonimmunogenic large tumors have been associated with an elusive serum factor. In this study, we identify this serum factor as tyrosine in its meta and ortho isoforms. In three different murine models of cancer that generate CR, both meta-tyrosine and ortho-tyrosine inhibited tumor growth. In addition, we showed that both isoforms of tyrosine blocked metastasis in a fourth model that does not generate CR but is sensitive to CR induced by other tumors. Mechanistic studies showed that the antitumor effects of the tyrosine isoforms were mediated, in part, by early inhibition of mitogen-activated protein/extracellular signal-regulated kinase pathway and inactivation of STAT3, potentially driving tumor cells into a state of dormancy. By revealing a molecular basis for the classical phenomenon of CR, our findings may stimulate new generalized approaches to limit the development of metastases that arise after resection of primary tumors, an issue of pivotal importance to oncologists and their patients. Cancer Res; 71(22); 7113–24. ©2011 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

  • R.A. Ruggiero, M.A. Isturiz, N. Speziale, O.D. Bustuoabad, and C.D. Pasqualini are members of Research Career of CONICET; Juan Bruzzo and Paula Chiarella are Fellows of CONICET.

  • Received February 17, 2011.
  • Revision received August 16, 2011.
  • Accepted September 2, 2011.